Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

被引：14

作者：

Collier, Anderson B., III ^{[1
]}

Krailo, Mark D. ^{[2
]}

Dang, Ha M. ^{[2
]}

DuBois, Steven G. ^{[3
,4
]}

Hawkins, Douglas S. ^{[5
]}

Bernstein, Mark L. ^{[6
]}

Bomgaars, Lisa R. ^{[7
]}

Reed, Damon R. ^{[8
,9
,10
]}

Gorlick, Richard G. ^{[11
]}

Janeway, Katherine A. ^{[3
,4
]}

机构：

[1] Univ Mississippi, Dept Pediat, Med Ctr, 2500 North Sate St, Jackson, MS 38219 USA

[2] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90007 USA

[3] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA

[4] Harvard Med Sch, Boston, MA 02115 USA

[5] Seattle Childrens Hosp, Dept Pediat, Seattle, WA USA

[6] Dalhousie Univ, IWK Hlth Ctr, Port Williams, NS, Canada

[7] Baylor Coll Med, Dept Pediat, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA

[8] Johns Hopkins All Childrens Hosp, Canc Ctr, St Petersburg, FL USA

[9] Johns Hopkins All Childrens Hosp, Blood Disorders Inst, St Petersburg, FL USA

[10] H Lee Moffitt Canc Ctr & Res Inst, Dept Individualized Canc Management, Tampa, FL USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

PEDIATRIC BLOOD & CANCER | 2021年 / 68卷 / 12期

关键词：

event-free survival; Ewing sarcoma; objective response; outcome; phase; 2; trials; relapsed; REFRACTORY SOLID TUMORS; II TRIAL; CHEMOTHERAPY; CRITERIA;

D O I：

10.1002/pbc.29333

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

引用

页数：5

共 20 条

[1] A Phase II Trial and Pharmacokinetic Study of Oxaliplatin in Children With Refractory Solid Tumors: A Children's Oncology Group Study [J].

Beaty, Orren, III ;

Berg, Stacey ;

Blaney, Susan ;

Malogolowkin, Marcio ;

Krailo, Mark ;

Knight, Ronald ;

Schaiquevich, Paula ;

Stewart, Clinton ;

Chen, Zhengjia ;

Nelson, Marvin ;

Voss, Stephan ;

Ivy, S. Percy ;

Adamson, Peter C. .

PEDIATRIC BLOOD & CANCER, 2010, 55 (03) :440-445

[2] SARC-CTOS imaging symposium: Introduction to the problem from a clinical perspective [J].

Benjamin, Robert S. .

ONCOLOGIST, 2008, 13 :1-3

[3] Ewing's sarcoma family of tumors: Current management [J].

Bernstein, Mark ;

Kovar, Heinrich ;

Paulussen, Michael ;

Randall, R. Lor ;

Schuck, Andreas ;

Teot, Lisa A. ;

Juergens, Herbert .

ONCOLOGIST, 2006, 11 (05) :503-519

[4] ON THE VARIANCES OF ASYMPTOTICALLY NORMAL ESTIMATORS FROM COMPLEX SURVEYS [J].

BINDER, DA .

INTERNATIONAL STATISTICAL REVIEW, 1983, 51 (03) :279-292

[5] Phase II trial of irinotecan in children with refractory solid tumors: A children's oncology group study [J].

Bomgaars, Lisa R. ;

Bernstein, Mark ;

Krailo, Mark ;

Kadota, Richard ;

Das, Soma ;

Chen, Zhengjia ;

Adamson, Peter C. ;

Blaney, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) :4622-4627

[6] A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study [J].

Bond, Mason ;

Bernstein, Mark L. ;

Pappo, Alberto ;

Schultz, Kirk R. ;

Krailo, Mark ;

Blaney, Susan M. ;

Adamson, Peter C. .

PEDIATRIC BLOOD & CANCER, 2008, 50 (02) :254-258

[7]

Grier, 2019, 2019 CTOS ANN M 2019

[8] Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study [J].

Hawkins, Douglas S. ;

Bradfield, Scott ;

Whitlock, James A. ;

Krailo, Mark ;

Franklin, Janet ;

Blaney, Susan M. ;

Adamson, Peter C. ;

Reaman, Gregory .

PEDIATRIC BLOOD & CANCER, 2006, 47 (06) :790-794

[9] Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group [J].

Jacobs, Shana ;

Fox, Elizabeth ;

Krailo, Mark ;

Hartley, Gwen ;

Navid, Fariba ;

Wexler, Leonard ;

Blaney, Susan M. ;

Goodwin, Anne ;

Goodspeed, Wendy ;

Balis, Frank M. ;

Adamson, Peter C. ;

Widemann, Brigitte C. .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :750-754

[10]

Kalbfleisch J.D., 2002, The Statistical Analysis of Failure Time Data, V2nd, P439

← 1 2 →